

1

DISCLAIMER

This presentation contains forward-looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.

2

straumann group

2

AGENDA

Highlights	Guillaume Daniellot
Financials	Yang Xu
Recent achievements & strategy	Guillaume Daniellot
Outlook 2024	Guillaume Daniellot
Q&A	Guillaume Daniellot, Yang Xu

3

straumanngroup

3



HIGHLIGHTS


Guillaume Daniellot, CEO

4

straumanngroup

4

STRAUMANN GROUP GREW 9.8 PERCENT ORGANICALLY WHILE INVESTING IN FUTURE GROWTH




⁵ ¹ Organic growth excluding FX and M&A effects ² Barring unforeseen events ³ Source: Straumann Group; calculation per smile: 2 implants or 1 clear aligner case start

straumanngroup

5

REMARKABLE PERFORMANCE WITH REGIONAL VARIATIONS

STRONG ORGANIC REVENUE GROWTH IN THE FOURTH QUARTER




⁶ * % of FY 2023 Group total revenue

6

CHINA: DYNAMIC PATIENT FLOW IN 2023

COVID-19 EFFECT AND ACCELERATED ADOPTION OF VBP



7


7



8

STRONG RESULT DESPITE CONTINUED FX HEADWINDS

REVENUE DEVELOPMENT BREAKDOWN (IN CHF MILLION, ROUNDED)



9

straumanngroup

9


GROWTH ACROSS ALL BUSINESSES

IMPLANTOLOGY KEPT ITS STRONG VOLUME GROWTH PACE

Tooth replacement and restoration



Tooth alignment



Digital solutions




10

straumanngroup

10

CORE GROSS MARGIN AT 74.3%

IN %, ROUNDED




11

straumanngroup

11

CORE EBIT MARGIN AT 25.1%

IN %, ROUNDED



12


straumanngroup

12

POSITIVE DEVELOPMENT OF FULL-YEAR FREE CASH FLOW

IN CHF MILLION, ROUNDED

Free Cashflow
 CHF 316m (13.1% of Net Revenue) in FY 2023
 vs.
 CHF 221m (9.5% of Net Revenue) in FY 2022



13

straumanngroup

13

FULL-YEAR CORE FINANCIALS AT A GLANCE

STRONG CURRENCY HEADWINDS IMPACTED BUSINESS PERFORMANCE

	FY 2023 ¹	% of Revenue	Margin change ²	Change in % ²	Comments
Revenue	2412			10.8%	
COGS	-619	25.7%		11.9%	
GROSS PROFIT	1793	74.3%	-30 bps		FX headwind -110 bps
Operating expenses	-1186	49.2%		7.7%	
EBIT	606	25.1%	+110 bps		FX headwind -200 bps
Financial result	-54	2.3%		88.4%	
Associates	-9	0.4%		25.1%	
Income tax	-102	4.2%		26.0%	
NET PROFIT	441	18.3%	-30 bps		FX headwind -220 bps
Basic EPS	2.76			8.9%	

¹⁴ ¹ in CHF million, rounded; except EPS ² FX adjusted

straumanngroup

14

CONTINUED CAPITAL ALLOCATION PRINCIPLES

FOCUS ON GROWTH INVESTMENT

In priority order

- 1 Reinvest in sustainable business growth
- 2 Maintain strong balance sheet
- 3 Pursue M&A to accelerate strategy
- 4 Maintain and increase dividend with earnings growth


15

straumanngroup

15

FURTHER INCREASE IN DIVIDEND AND SHAREHOLDER BASE

- Proposed¹ dividend of total CHF 0.85 per share; thereof CHF 0.40 to be paid from capital contribution reserve
- Payable on 18 April 2024 (ex-dividend: 16 April 2024)
- Core payout ratio of 30.8%



16


¹ A dividend for the year ended 31 December 2023 of CHF0.85 per share will be proposed at the AGM on 12 April 2024

straumanngroup

16




17



18

TRANSFORMATION OF THE GROUP OVER THE YEARS

FROM IMPLANTOLOGY TO ORAL CARE PROVIDER WITH LARGE FOOTPRINT IN HIGH GROWTH MARKETS



¹⁹ Source: Straumann Group estimates – in CHF revenue

CULTURE DRIVES STRATEGY


Engagement score

81

+3 points above global benchmark


Response rate

91%



²⁰

OUR PILLARS TO SUCCESS



Innovation



Education



Clinical evidence




21

straumanngroup

21

INNOVATION AND EDUCATION: KEY LEVERS FOR PREMIUM IMPLANTOLOGY GROWTH



iEXCEL

Innovation



GalvoSurge

Education




22

straumanngroup

22

GEOGRAPHICAL EXPANSION AND INNOVATION DRIVE CHALLENGER BRANDS

VALUE IMPLANT MARKET ~31 MILLION IMPLANTS



23




straumanngroup

23

CLEARCORRECT STRENGTHENED ITS VALUE PROPOSITION

Innovation



24

Education

100+

TRAINED SPEAKERS
GLOBALLY

15+

CLEARCORRECT SYMPOSIUMS/
EVENTS HELD TO-DATE



straumanngroup

24

DRIVING DIGITAL TRANSFORMATION IN DENTISTRY



Full portfolio of
intraoral scanners



AI-driven dentistry
applications



Treatment
solutions


25

straumanngroup

25

... AND CREATING AN INTEGRATED CUSTOMER EXPERIENCE

MAJOR PROGRESS ON STRAUMANN AXS



26

NURTURING OUR CULTURE – A COMPETITIVE ADVANTAGE

CULTIVATING A DIGITAL MINDSET AND SKILLSET



27

INTERNAL SUCCESSION PLAN FOR EXECUTIVE MANAGEMENT

SUCCESSION PLAN STARTING FROM JULY 2024

Wolfgang Becker – to retire
Head of the EMEA region



Holger Haderer
Head of Implantology,
New role: Head of the EMEA region



Andreas Utz
MD of Straumann Group Germany,
New role: Head of Implantology



28

straumanngroup

28

A STRONG CULTURE BUILDS A SUSTAINABLE COMPANY

PROGRESS ON OUR SUSTAINABILITY GOALS

Smiles

5.6m

Education activities in low- and middle-income countries

28%

Leadership positions

40%

female

Employee say they have good opportunities to grow and learn

77 score

Net-zero emissions

2040

Renewable electricity

93%

Acting with responsibility
Zero tolerance policy maintained

29

Our sustainability framework

ADVANCING
ORAL CARE

EMPOWERING
PEOPLE

ACTING WITH
RESPONSIBILITY

OUR PURPOSE
To unlock the potential of people's lives

CARING FOR THE
PLANET AND
SOCIETY

29

CONTINUED SIGNIFICANT INVESTMENT IN GROWTH IN 2023 WHICH WILL CONTINUE



CADCAM & milling, Mansfield, US



China Campus, Shanghai



Straumann implant manufacturing, Villeret CH



Neodent & Clear Correct manufacturing, Curitiba, BRA



Medentika manufacturing, Calw, GER



Group Technology & Innovation, Arlesheim, CH

Employees

>11 100

Capital expenditure

CHF 189m

30

straumanngroup

30



31

OUTLOOK 2024
BARRING UNFORESEEN CIRCUMSTANCES

<p>Market environment and assumption</p> <ul style="list-style-type: none">• Uncertain economic environment remains• Group believes global patient flow should remain stable• Outgrowing market vs. prior year	<p>Revenue and profitability</p> <ul style="list-style-type: none">• Organic revenue growth in the high single-digit percentage range• Profitability at around 26% at constant 2023 currency rates or between 24% and 25% including expected FX headwind
---	--

Growth ambition 2030 confirmed

32 **straumanngroup**

32



33



Published today

34

CALENDAR OF UPCOMING EVENTS

2024	Event	Location
28-29 February	ZKB Swiss Roadshow	Zürich and Geneva
5-6 March	Bernstein UK Roadshow	London
7 March	Bernstein France Roadshow	Paris
20 March	Kepler Cheuvreux Swiss Seminar	Zurich
26-28 March	Citi USA Roadshow	Boston and New York
30 April	Q1 2024 Results	
7 May	Jefferies Singapore Roadshow	Singapore
15 May	Deutsche Bank Germany Roadshow	Frankfurt
16 May	Mirabaud Swiss Equity Conference	Geneva
4-6 June	BNP Paribas Exane CEO Conference	Paris
10-12 June	Stifel Swiss Equities Conference	Interlaken


35

straumanngroup


35

CURRENCY EXPOSURE


Revenue breakdown FY 2023



Total cost breakdown FY 2023



Exchange rates development 2022 – 2023



	Average exchange rates (rounded)	Closing			FX sensitivity (+/- 10%) on FY	
		2022	2023	Dec 2023	Revenue	EBIT
1	EURCHF	1.004	0.973	0.933	+/- 70m	+/- 15m
1	USDCHF	0.950	0.899	0.843	+/- 63m	+/- 34m
1	BRLCHF	0.184	0.180	0.174	+/- 15m	+/- 0m
1	CNYCHF	0.141	0.127	0.119	+/- 26m	+/- 20m

36

straumanngroup

36

CORE RESULTS RECONCILIATION

(in CHF 1'000)	IFRS	PPA amortization	Impairments	Restructuring	Other	CORE
Revenue	2 411 819					2 411 819
Cost of goods sold	(624 554)	4 502		1 143		(618 909)
Gross profit	1 787 265	4 502		1 143		1 792 910
Other income	7 075			(10)		7 065
Distribution expense	(452 036)	5 443		0		(446 593)
Administrative expense	(931 332)	4 264	152 906	27 202		(746 960)
Operating profit	410 973	14 208	152 906	28 336		606 422
Finance income	110 890					110 890
Finance expense	(167 173)			1 930		(165 244)
Share of result of associates	(9 068)					(9 068)
Profit before income tax	345 621	14 208	152 906	30 265		543 000
Income tax expense	(98 811)	(3 101)	(331)	482		(101 761)
NET PROFIT	246 810	11 107	152 575	30 747		441 239
Attributable to:						
Shareholders of the parent company	246 072	11 011	152 575	30 747		440 405
Non-controlling interests	738	95				833
Basic earnings per share (in CHF)	1.54					2.76
Diluted earnings per share (in CHF)	1.54					2.76
Operating profit	410 973	14 208	152 906	28 336		606 422
Depreciation & amortization	289 550	(9 834)	(152 906)	(6 020)		120 790
EBITDA	700 523	4 374		22 316		727 212

37

straumanngroup

37

THE FOLLOWING EFFECTS WERE DEFINED AS NON-CORE ITEMS

2023

- Special items and amortization of acquisition-related intangible assets amounting to CHF 11 million
- One-off costs of CHF 31 million resulting from various restructuring measures across the regions
- One-time, non-cash impairment charges amounting to CHF 153 million, mainly related to goodwill impairment recognized for the DrSmile business

2022

- Amortization of acquisition-related intangible assets amounting to CHF 38 million (mainly related to the accelerated amortization of the PlusDental brand)
- The accelerated amortization of the PlusDental brand as well as the restructuring costs amount to CHF 9 million and were triggered by the Group's brand conclusion to run its direct-to-consumer clear aligner marketing business in Europe exclusively under the DrSmile brand

38

straumanngroup

38

REPORTED FINANCIALS AT A GLANCE

	FY 2023 ¹	% of revenue	Margin change ²	Change in % ²	Comments
Revenue	2'412			10.8%	
COGS	-625	25.9%		12.6%	
GROSS PROFIT	1'787	74.1%	-40 bps		FX headwind -110 bps
Operating expenses	-1'376	57.1%		18.2%	
EBIT	411	17.0%	-390 bps		FX headwind -210 bps
Financial result	-56	2.3%		95.1%	
Associates	-9	0.4%		25.1%	
Income tax	-99	4.1%		60.4%	
NET PROFIT	247	10.2%	-630 bps		FX headwind -220 bps
Basic EPS	1.54			-31.5%	

³⁹ ¹ in CHF million, rounded; except EPS ² FX adjusted

straumanngroup


39

EMEA AND NORTH AMERICA REPORT STRONG GROWTH

EMEA
44%* of Group



North America
28%* of Group



⁴⁰ *Refers to full-year

straumanngroup


40

APAC FACES HEADWINDS IN CHINA AND LATAM GROWS FAST

Asia Pacific
19% of Group*



Latin America
9% of Group*



41



42